Illustration of a T cell attacking a tumor cell
Nadin Al Shukor, Associate Scientist, Ghent, BelgiumOur Oncology Pipeline
We have more than a dozen next-generation molecules in the clinic, each with a distinctive mechanism of action against either hematologic malignancies or solid tumors.
Follow the Science
Our R&D teams follow the science to find treatments for people living with cancer.
Voices from the Lab: Nizar El Murr on Immuno-oncology
Our Multi-Front Attack on Cancer
John Reed and Frank Nestle discuss how we’re building an R&D pipeline to address critical gaps in cancer care
Bolstering the Immune System
Our immuno-oncology teams are working on ways to boost the immune system to better detect and attack tumors. And our molecular oncology teams are designing powerful precision drugs to either destroy cancer cells or activate immune cells locally.
Rethinking Oncology Drug Development
Our culture of collaboration empowers our teams to achieve real change for people battling cancer.
Technology Toolbox
We’ve reshaped our footprint in oncology, expanding our capabilities with state-of-the-art technologies in immuno-oncology, molecular oncology, and genomic medicine.
Collaboration
To further our bold vision of generating multiple candidates every year, we collaborate with innovative partners to break new ground in oncology.
Patient Centricity
By listening, learning, and keeping patients at the center of everything we do, we can advance the science and make a lasting difference in people’s lives.
More About Oncology
Cancer Under Siege
Sanofi’s Commitment to Oncology
Your Health: Oncology
Selected publications
- LaMarche MJ (2022) Think Biologically, Act Chemically. J Medicinal Chem; DOI: 10.1021/acs.jmedchem.2c01121
- Manandhar M, Chun E, Romesberg FE (2021) Genetic Code Expansion: Inception, Development, Commercialization. J Am Chem Soc 143:4859-4878; DOI: 10.1021/jacs.0c11938
- Mitra-Kaushik S, Mehta-Damani A, Stewart JJ, et al. (2021) The Evolution of Single-Cell Analysis and Utility in Drug Development. AAPS J 23:98; DOI: 10.1208/s12248-021-00633-6
Page updated August 2023